Our Mission

The GLP-1 Collective supports individuals using GLP-1 medications by removing barriers to access, offering financial assistance, educating and empowering patients, and building a community where no one feels alone in their journey.

Our financial assistance program is in development. We will share updates on ways to get involved as the program grows.

Who We Are

  • Christie Clutter

    Director

  • Amanda Bonello

    Founder & Executive Director

  • Sablle Titus

    Director

How We Began

It Started with a Petition

Our story starts before the GLP-1 Collective nonprofit existed. In November 2024, founder Amanda Bonello launched a national petition calling for affordable access to GLP-1 medications. The petition quickly gained momentum, leading to nine media interviews and growing national attention.

That wave of grassroots support inspired her to launch the GLP-1 Collective Podcast to share patient stories and put a human face to the fight for access. As the movement grew, it became clear that a dedicated nonprofit was needed to carry this mission forward.

In January 2025, the GLP-1 Collective became an incorporated nonprofit, committed to advancing equitable, affordable access to GLP-1 medications and empowering the patient community through advocacy, education, and storytelling.

Our FAQs

  • We support anyone connected to the GLP-1 journey — whether you’re taking the medication, exploring if it’s right for you, or supporting a loved one. Our work includes education to help you navigate treatment, campaigns to fight stigma, programs that empower patients to advocate for themselves, community support networks, and charitable programs for those facing cost barriers.

  • GLP-1 medications are life-changing for many people managing conditions like diabetes, obesity, heart disease, PCOS, and more. Yet high prices, insurance denials, and supply shortages keep far too many from getting treatment. Every day without access means worsening health, higher long-term costs, and unnecessary suffering — which is why we push for solutions now, not years from now.

  • We are an independent, patient-led nonprofit. We do not accept funding from pharmaceutical companies in exchange for endorsements, and we will never allow outside interests to dictate our advocacy, messaging, or programs. We will work with industry when it benefits patients — but our loyalty is always to the community.

  • We run education campaigns, host community support groups, create resource guides, advocate for policy change, and fight stigma through storytelling. We also operate charitable programs such as patient starter kits, access navigation tools, and prescription assistance resources — all designed to make GLP-1 care more affordable, approachable, and equitable.

  • You can join our advocacy campaigns, share your story to help fight stigma, connect people to our resources, and participate in events. The nonprofit’s charitable funding comes through grants and our GoFundMe campaign.

  • No. We are not a medical provider and do not offer prescriptions or individual medical advice. We provide education, navigation resources, and advocacy to help patients access care from licensed healthcare professionals.

  • Our legal home is in Iowa, but our advocacy and programs serve people nationwide. We collaborate with patients, providers, and organizations across the United States.

  • Yes. We partner with nonprofits, advocacy groups, and mission-aligned organizations to expand our impact. All partnerships are evaluated for alignment with our values and compliance requirements.

  • We are solution-agnostic. That means we support any safe, legal, and effective pathway to GLP-1 treatment that puts patients first. Whether a medication is brand-name, biosimilar, or compounded, what matters most is access, safety, and affordability.

  • We refuse funding that would compromise our mission or force us to promote a product or company. Our programs and messaging are created in service to patients — not sponsors, political agendas, or corporate interests. Transparency in funding and operations is part of our core values.

  • It means we don’t lock ourselves into one “right” path for treatment access. Instead, we evaluate every option — brand-name, generic, compounded, manufacturer programs, insurance strategies, and policy change — and advocate for whichever mix will get safe, affordable medications to the people who need them most.